Published: 18 January 2021
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease
Published: 5 January 2021
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
ViGeneron has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.
Published: 1 December 2020
ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership For Next-Generation Ophthalmic Gene Therapy
ViGeneron has announced a strategic partnership with WuXi Advanced Therapies Inc., a leading Contract, Testing, Development and Manufacturing Organization to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.
Published: 28 November 2019
ViGeneron Announces Closing of Series A Financing to Drive Development of Next Generation Gene Therapy Pipeline
ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. Funds will advance development of ViGeneron’s […]